Cryobanks
International (BTEM)
"Cryobanks
represents a unique established facility involved in technology that has the
potential to be highly profitable while being directly responsible for the
saving of lives and discovery of new therapies."
Website:
www.cryo-intl.com
Cryobanks Investor
Highlights
- Cryobanks is a leader in the collection,
processing, and banking of stem cells derived from the umbilical cord
immediately after birth.
- Cryobanks has a current cord blood bank
inventory of over 8,500 units, plus over 1,000 research units and is
expecting substantial growth with its new licenses.
- The Company has closed
eight international licensing agreements; one in Athens, Greece and seven in
India, and has at least 40 additional licensing agreements in various stages
of development throughout Europe and the rest of the world.
- In recent years, cord blood transplants (CBTs)
have become widely recognized as a safe, effective, and in many ways
preferable, alternative to bone marrow transplant. There is tremendous
potential need for CBTs in the United States and worldwide.
- Cryobanks has material transfer agreements
with research departments in numerous major medical facilities and
universities.
- The Company announced that it has processed
and stored over 150 units of cord blood in its first month of operation in
Greece.
- Cryobanks International India Private Limited
is scheduled to open in June of 2006 and will become home to one of the
largest cord blood processing laboratories in the country. In addition to
the New Dehli location, Cryobanks International India Private Limited will
open six other facilities within the next eighteen months.
- Recently established a strategic partnership
with the NMDP in Puerto Rico in an effort to expand their cord blood
donation program.
- The Company has partnered in two grants from
the State of Florida investigating the use of cord blood to treat spinal
cord repair and Acute Lymphocytic Leukemia.
- Is the only facility accepting donated cord
blood units from anywhere in the continental United States, every day of the
week.
- Cryobanks is accredited by the American
Association of Blood Banks and registered with the Food and Drug
Administration.
- The stem cell (cord blood) storage market is
estimated at over $2 billion worldwide and growing rapidly.
To learn more about Cryobanks
International including Management, Operations and Chart, please visit www.smallcapreview.com/btem.htm
Overview
Cryobanks International, Inc. is a corporation
which is to be acquired by BioStem, Inc. (OTC BB: BTEM). Cryobanks International
is a leader in the collection, processing and banking of umbilical cord blood
stem cells. Cryobanks has a current cord blood bank inventory of over 8,500
units, plus over 1,000 research units.
The units of cord blood (CB) are processed and
stored by the company for use in unrelated transplants (where the donor is a
histocompatible match, but is anonymous and unrelated to the recipient) and for
personal storage and use. In recent years, cord blood transplants (CBTs) have
become widely recognized as a safe, effective, and in many ways preferable,
alternative to bone marrow transplant (BMT). There is tremendous potential need
for CBTs in the United States and worldwide. Cryobanks International is well
poised to help meet that need, equipped with an inventory of over 8,500 cord
blood units.
Profile
Founded in 1993, Cryobanks International is a
pioneer in the collection, isolation, and storage technologies for cord blood
stem cells. Cryobanks expanded its scope of business into the field of cord
blood banking in mid-1995. The company is focused on providing high-quality
umbilical cord blood stem cell processing, and storage for both private family
use and public donation purposes.
The Company's goal is to advance the field in
areas that will save lives while becoming the largest provider of cord blood
stem cells (CBSCs) for transplant and research purposes in the world. Currently,
Cryobanks is the only facility accepting donated cord blood units from anywhere
in the continental United States, every day of the week.
The Company does not permit involvement in any
research that is deemed controversial including cloning, embryonic, or cosmetic
research. It is the mission of Cryobanks to ensure that anyone in need of a cord
blood stem cell transplant will have a matched unit to access.
Cryobanks is an NMDP Bank accredited by the
American Association of Blood Banks (AABB) in hematopoietic progenitor cell
activities, licensed for tissue banking operations by the New York State
Department of Health and registered with the Food and Drug Administration.
Recent News and Press
Releases
Cryobanks
Begins Road Show in New York
Cryobanks
International Recognizes The University of Minnesota for Recent Stem Cell
Discovery
Cryobanks
International Inc. Commends the European Commission for Setting Standards for
Human Cell & Tissue Practices
Cryobanks
International Services Athens Quickly Gains Acceptance in Greece
Cryobanks
International Inc. Signs Letters of Intent to License Cord Blood Banking
Technology
Cryobanks
International, Inc. and the National Marrow Donor Program Team to Facilitate
Cord Blood Donations in Puerto Rico
Cryobanks
International, Inc. Licenses Cord Blood Processing System in India
Cryobanks
International, Inc. Expands to Greece
President
signs H.R. 2520 funding stem cell research of umbilical cord blood
For the latest Quote and News on BTEM
Click Here.
Management
Cryobanks International relies on
a highly acclaimed team of scientists and doctors to provide guidance to its
operations and activities. Dr. Sanford Lederman heads a team of nine
professionals forming the Company's Scientific and Medical Board of Advisors (
S.A.M.B.A.). For a complete listing, please see http://www.cryo-intl.com/medical-board.html.
FORWARD LOOKING STATEMENTS
This report contains "forward-looking
statements" by BioStem, Inc. These statements relate to future events or
financial performance and transactions, and involve known and unknown risks,
uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements, to be materially different from those
contemplated by the forward-looking statements. There can be no assurance that
the acquisition described herein will successfully close. The company undertakes
no ongoing obligation, other than that imposed by law, to update these
statements. Factors that could affect results, levels of activity, performance
or achievements and cause them to materially differ from those contained in the
forward-looking statements include the failure to complete the acquisition of
Cryobanks.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of BTEM, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
was compensated eight thousand dollars by a third party (DC) for its efforts
in presenting the Cryobanks International profile on its website and
distributing it to its database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as ???expects??™???, ???will,??? ???anticipates,???
???estimates, ???believes,??? or that by statements indicating certain
actions ???may,??? ???could,??? or ???might??? occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|
